Target intelligence / Profile preview

Autophagy-dependent MHC class II (MHC-II) antigen presentation machinery

Molecular classification
Other
01

Overview

The Autophagy-dependent MHC class II (MHC-II) antigen presentation machinery is a complex cellular system that facilitates the delivery of intracellular antigens to the MHC-II pathway for presentation to CD4+ T cells (Münz, 2012, Frontiers in Immunology). Traditionally, MHC-II molecules are dedicated to presenting exogenous antigens, but this machinery allows for the processing of endogenous proteins, including viral and self-antigens, via macroautophagy (Schmid et al., 2007, Immunity). The process involves the sequestration of cytoplasmic components into autophagosomes, which then fuse with MHC-II-loading compartments (MIICs) where peptides are loaded onto MHC-II dimers (Crotzer & Blum, 2009, Journal of Immunology). This pathway plays a vital role in immune surveillance and the maintenance of self-tolerance, and its dysfunction is implicated in autoimmune diseases and the evasion of anti-tumor immunity (Zhou et al., 2005, Nature). Therapeutic modulation of this machinery is currently achieved through non-specific agents such as hydroxychloroquine, which blocks lysosomal degradation, or mTOR inhibitors like rapamycin, which stimulate autophagic flux (Levine & Kroemer, 2019, Cell).

Other names
Autophagy-mediated MHC II presentationMacroautophagy-dependent MHC II antigen processingEndogenous MHC II presentation pathway
02

Mechanism of action

Modulation of autophagic flux and lysosomal degradation to alter the repertoire of antigens presented on MHC class II molecules.

03

Biological functions

Immune responseAntigen processing and presentationAutophagyProteostasis
04

Disease associations

Autoimmune diseaseCancerInfectionInflammation
05

Safety considerations

Systemic immunosuppressionImpairment of cellular proteostasisPotential for neurotoxicity due to autophagy inhibitionRisk of exacerbating autoimmune reactions
06

Interacting drugs

Chloroquine

3 more in the full profile.

07

Biomarkers

LC3-II/LC3-I ratiop62 (SQSTM1) protein levelsMHC class II surface expressionCD4+ T-cell activation markers

Beyond the preview

Go deeper on Autophagy-dependent MHC class II (MHC-II) antigen presentation machinery.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autophagy-dependent MHC class II (MHC-II) antigen presentation machinery.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call